| Active ingredient (INN) | Everolimus |
|---|---|
| Brand names | Afinitor |
| ATC level 5 | L01EG02 |
| ATC level 4 | L01EG |
| Therapeutic category | Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper |
| Controlled substance | No |
| Marketing-authorisation holders | Pharmacor Pty Ltd, HIKMA PHARMACEUTICALS USA INC., Novartis Pharmaceuticals Australia Pty Ltd |
| Registrations on file | 23 |
| Patient information leaflet (PIL) | Not on file |
| Summary of product characteristics (SPC) | Not on file |
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| Pharmacor | 0.5 mg | — | 🇦🇺 AU | Pharmacor Pty Ltd | Active |
| EVEROCAN everolimus | 0.25 mg | — | 🇦🇺 AU | Pharmacor Pty Ltd | Active |
| Pharmacor | 1 mg | — | 🇦🇺 AU | Pharmacor Pty Ltd | Active |
| EVEROCAN everolimus | 0.5 mg | — | 🇦🇺 AU | Pharmacor Pty Ltd | Active |
| Pharmacor | 0.25 mg | — | 🇦🇺 AU | Pharmacor Pty Ltd | Active |
| EVEROCAN everolimus | 0.75 mg | — | 🇦🇺 AU | Pharmacor Pty Ltd | Active |
| EVEROCAN everolimus | 1 mg | — | 🇦🇺 AU | Pharmacor Pty Ltd | Active |
| Pharmacor | 0.75 mg | — | 🇦🇺 AU | Pharmacor Pty Ltd | Active |
| Everolimus | .25mg/1 | tablet | 🇺🇸 US | HIKMA PHARMACEUTICALS USA INC. | Active |
| Everolimus | .5mg/1 | tablet | 🇺🇸 US | HIKMA PHARMACEUTICALS USA INC. | Active |
| Everolimus | .75mg/1 | tablet | 🇺🇸 US | HIKMA PHARMACEUTICALS USA INC. | Active |
| Everolimus | 2.5mg/1 | tablet | 🇺🇸 US | HIKMA PHARMACEUTICALS USA INC. | Active |
| Everolimus | 5mg/1 | tablet | 🇺🇸 US | HIKMA PHARMACEUTICALS USA INC. | Active |
| Everolimus | 10mg/1 | tablet | 🇺🇸 US | HIKMA PHARMACEUTICALS USA INC. | Active |
| Everolimus | 7.5mg/1 | tablet | 🇺🇸 US | HIKMA PHARMACEUTICALS USA INC. | Active |